Wallonia, leading the future of nuclear medicine

Wallonia has emerged as a global leader in nuclear medicine, with strengths across isotope production, radiopharmaceutical innovation, and patient care. As global demand grows, Wallonia is well placed to build on this momentum and strengthen its role as a centre of innovation.

Nuclear medicine uses radioactive substances for diagnostics and targeted therapies, playing an important role in personalised medicine. Wallonia benefits from a fully integrated value chain and hosts leading organisations supporting research and clinical applications.

While market opportunities are expanding rapidly, challenges remain, including limited coordination between stakeholders, operational bottlenecks, talent shortages, complex regulations, and low public awareness. Addressing these will be key to sustaining growth.

A unified national strategy, improved infrastructure, regulatory modernisation, talent development, and greater awareness are essential to securing Wallonia’s position as a world-class hub for nuclear medicine—delivering benefits to patients, industry, and the economy.

About this study

This strategic study, conducted by BioWin with analytical support from PwC, synthesises insights from 13 expert interviews and 21 survey responses across the nuclear medicine value chain. Methodologies included SWOT analyses to benchmark Wallonia’s positioning, identify barriers, and recommend comprehensive actions for sustainable growth.

Authors